Werth VP, Hejazi E, Pena SM, Haber J, et al. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease A Randomized Clinical Trial. J Invest Dermatol 2022 Apr 28. pii: S0022-202X(22)00295.
PMID: 35490744